FORE Biotherapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference

PHILADELPHIA – May 10, 2024 – FORE Biotherapeutics today announced that the Company will be presenting at the 2024 RBC Capital Markets Global Healthcare Conference. The presentation will take place on Wednesday, May 15, 2024 at 9:00-9:25 AM ET.

William Hinshaw, Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact your RBC Capital Markets salesperson or Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit or follow us on X (formerly Twitter) and LinkedIn.

Investors and Media:

Argot Partners

moc.s1716244510rentr1716244510aptog1716244510ra@oi1716244510BeroF1716244510 | 20171624451091.0017162445106.2121716244510